Comparing Edap Tms (NASDAQ:EDAP) and SiBone (NASDAQ:SIBN)

SiBone (NASDAQ:SIBN) and Edap Tms (NASDAQ:EDAP) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, profitability, analyst recommendations, institutional ownership and valuation.

Earnings & Valuation

This table compares SiBone and Edap Tms”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SiBone	$200.93 million	2.86	-$18.90 million	($0.44)	-29.57
Edap Tms	$70.53 million	1.87	-$29.25 million	($0.77)	-4.58

SiBone has higher revenue and earnings than Edap Tms. SiBone is trading at a lower price-to-earnings ratio than Edap Tms, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares SiBone and Edap Tms’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
SiBone	-9.41%	-11.01%	-8.12%
Edap Tms	-41.24%	-100.07%	-37.38%

Analyst Ratings

This is a breakdown of current recommendations and price targets for SiBone and Edap Tms, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SiBone	1	0	6	0	2.71
Edap Tms	1	2	0	0	1.67

SiBone currently has a consensus price target of $24.67, suggesting a potential upside of 89.60%. Edap Tms has a consensus price target of $2.00, suggesting a potential downside of 43.34%. Given SiBone’s stronger consensus rating and higher possible upside, equities analysts plainly believe SiBone is more favorable than Edap Tms.

Volatility & Risk

SiBone has a beta of 0.69, suggesting that its share price is 31% less volatile than the S&P 500. Comparatively, Edap Tms has a beta of -0.08, suggesting that its share price is 108% less volatile than the S&P 500.

Insider & Institutional Ownership

98.1% of SiBone shares are held by institutional investors. Comparatively, 62.7% of Edap Tms shares are held by institutional investors. 4.0% of SiBone shares are held by insiders. Comparatively, 0.2% of Edap Tms shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

SiBone beats Edap Tms on 13 of the 14 factors compared between the two stocks.

About SiBone

SI-BONE, Inc., a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products. The company also provides iFuse-3D, a titanium implant that combines the triangular cross-section of the iFuse implant with the proprietary 3D-printed porous surface and fenestrated design; iFuse-TORQ, a set of 3D-printed threaded implants designed to treat pelvic trauma; and iFuse Bedrock Granite implant provides sacroiliac fusion and sacropelvic fixation as a foundational element for segmental spinal fusion. It markets its products primarily with a direct sales force, as well as through agents and resellers. SI-BONE, Inc. was incorporated in 2008 and is headquartered in Santa Clara, California.

About Edap Tms

EDAP TMS SA is a holding company, which, through its subsidiary, engages in the development, production, and marketing of minimally invasive medical devices for urological diseases. It operates through the High Intensity Focused Ultrasound (HIFU) and Urology Devices and Services (UDS) segments. The HIFU segment develops, manufactures, and markets devices for the minimally invasive ablation of certain types of localized tumors using HIFU technology. The UDS segment focuses on the development, marketing, manufacturing, and servicing of medical devices for the minimally invasive diagnosis or treatment of urological disorders, mainly urinary stones, and other clinical indications. The company was founded on December 3, 1979 and is headquartered in Vaulx-en-Velin, France.